Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Satoi S, Yamaue H, Kato K, Takahashi S, Hirono S, Takeda S, Eguchi H, Sho M, Wada K, Shinchi H, Kwon AH, Hirano S, Kinoshita T, Nakao A, Nagano H, Nakajima Y, Sano K, Miyazaki M, Takada T.

J Hepatobiliary Pancreat Sci. 2013 Aug;20(6):590-600. doi: 10.1007/s00534-013-0616-0.

PMID:
23660962
2.

Adjuvant surgical therapy for patients with initially-unresectable pancreatic cancer with long-term favorable responses to chemotherapy.

Kato K, Kondo S, Hirano S, Tanaka E, Shichinohe T, Tsuchikawa T, Matsumoto J.

J Hepatobiliary Pancreat Sci. 2011 Sep;18(5):712-6. doi: 10.1007/s00534-011-0391-8.

PMID:
21455748
3.

Role of adjuvant surgery in initially unresectable pancreatic cancer after long-term chemotherapy or chemoradiation therapy: survival benefit?

Opendro SS, Satoi S, Yanagimoto H, Yamamoto T, Toyokawa H, Hirooka S, Yamaki S, Inoue K, Matsui Y, Kwon AH.

J Hepatobiliary Pancreat Sci. 2014 Sep;21(9):695-702. doi: 10.1002/jhbp.119. Epub 2014 May 19.

PMID:
24841048
4.

Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.

Takahashi S, Kinoshita T, Konishi M, Gotohda N, Kato Y, Kinoshita T, Kobayashi T, Mitsunaga S, Nakachi K, Ikeda M.

J Hepatobiliary Pancreat Sci. 2011 Jul;18(4):567-74. doi: 10.1007/s00534-011-0371-z.

PMID:
21331805
5.

Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery.

Kato H, Usui M, Isaji S, Nagakawa T, Wada K, Unno M, Nakao A, Miyakawa S, Ohta T.

J Hepatobiliary Pancreat Sci. 2013 Aug;20(6):601-10. doi: 10.1007/s00534-013-0595-1.

PMID:
23494611
6.

Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.

Mirkin KA, Greenleaf EK, Hollenbeak CS, Wong J.

Cancer. 2016 Oct;122(19):2979-87. doi: 10.1002/cncr.30163. Epub 2016 Jun 21.

7.

Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.

Bickenbach KA, Gonen M, Tang LH, O'Reilly E, Goodman K, Brennan MF, D'Angelica MI, Dematteo RP, Fong Y, Jarnagin WR, Allen PJ.

Ann Surg Oncol. 2012 May;19(5):1663-9. doi: 10.1245/s10434-011-2156-7. Epub 2011 Dec 1.

PMID:
22130621
8.

Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery.

Donahue TR, Isacoff WH, Hines OJ, Tomlinson JS, Farrell JJ, Bhat YM, Garon E, Clerkin B, Reber HA.

Arch Surg. 2011 Jul;146(7):836-43. doi: 10.1001/archsurg.2011.152.

PMID:
21768431
9.

Beyond the dollar: Influence of sociodemographic marginalization on surgical resection, adjuvant therapy, and survival in patients with pancreatic cancer.

Kagedan DJ, Abraham L, Goyert N, Li Q, Paszat LF, Kiss A, Earle CC, Mittmann N, Coburn NG.

Cancer. 2016 Oct 15;122(20):3175-3182. doi: 10.1002/cncr.30148. Epub 2016 Jul 8.

10.

Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.

Aoyama T, Murakawa M, Katayama Y, Shiozawa M, Ueno M, Morimoto M, Yoshikawa T, Rino Y, Masuda M, Morinaga S.

Hepatogastroenterology. 2015 Mar-Apr;62(138):472-7.

PMID:
25916085
11.

Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer.

Morganti AG, Falconi M, van Stiphout RG, Mattiucci GC, Alfieri S, Calvo FA, Dubois JB, Fastner G, Herman JM, Maidment BW 3rd, Miller RC, Regine WF, Reni M, Sharma NK, Ippolito E, Valentini V.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):911-7. doi: 10.1016/j.ijrobp.2014.07.024. Epub 2014 Sep 11.

PMID:
25220717
12.
13.

Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival.

Nordby T, Hugenschmidt H, Fagerland MW, Ikdahl T, Buanes T, Labori KJ.

Eur J Surg Oncol. 2013 Jun;39(6):559-66. doi: 10.1016/j.ejso.2013.02.020. Epub 2013 Mar 14.

PMID:
23498362
14.

Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?

Chen KT, Devarajan K, Milestone BN, Cooper HS, Denlinger C, Cohen SJ, Meyer JE, Hoffman JP.

Ann Surg Oncol. 2014 Feb;21(2):662-9. doi: 10.1245/s10434-013-3396-5. Epub 2013 Nov 26.

PMID:
24276638
15.

Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival.

Kadera BE, Sunjaya DB, Isacoff WH, Li L, Hines OJ, Tomlinson JS, Dawson DW, Rochefort MM, Donald GW, Clerkin BM, Reber HA, Donahue TR.

JAMA Surg. 2014 Feb;149(2):145-53. doi: 10.1001/jamasurg.2013.2690.

PMID:
24306217
16.

Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.

Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T, Yano M, Nakaizumi A, Uehara H, Tomita Y, Nishiyama K.

Ann Surg. 2009 Jul;250(1):88-95. doi: 10.1097/SLA.0b013e3181ad65cc.

PMID:
19561477
17.

Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis.

Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeger Y, B├╝chler MW, Weitz J.

Ann Surg. 2011 Dec;254(6):882-93. doi: 10.1097/SLA.0b013e31823ac299. Review.

PMID:
22064622
18.

Clinical Significance of Adjuvant Surgical Resection for Initially Unresectable Pancreatic Cancer Responsive to Arterial Infusion Chemotherapy.

Doi T, Homma H, Akiyama T, Mezawa S, Takahashi M, Ohi M, Tanaka S, Morii K, Kogawa K, Takeuchi M, Hirata K, Hirano S.

Hepatogastroenterology. 2014 May;61(131):828-33.

PMID:
26176081
19.

Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.

Okabayashi T, Nishimori I, Nishioka A, Yamashita K, Sugimoto T, Dabanaka K, Maeda H, Kohsaki T, Ogawa Y, Kobayashi M, Onishi S, Hanazaki K.

Oncol Rep. 2008 Sep;20(3):651-6.

PMID:
18695919
20.

Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005).

Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, Jatoi A, McWilliams RR, Kim GP, Bhatia S, Iott MJ, Gunderson LL.

J Clin Oncol. 2008 Jul 20;26(21):3511-6. doi: 10.1200/JCO.2007.15.8782.

PMID:
18640932

Supplemental Content

Support Center